Proactive Adverse Effect Management for Patients on Therapy for Endometrial Cancer

Commentary
Video

Nurse Practitioner Kimberly Halla explains the proactive measures she takes to ensure patients with endometrial cancer are prepared to experience and manage the adverse effects of treatment.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Gynecologic Cancers
Related Content
Rendering of endometrial cancer cells

Biocartis Launches qPCR POLE/POLD1 Mutational Assay

Bridget Hoyt
April 4th 2025
Article

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer.

The Vitals

Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

Lindsay Fischer
June 15th 2023
Podcast

Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.

Anatomical rendering of the female reproductive system with a tumor in the uterine lining

Palbociclib Plus Letrozole May Increase PFS for ER+ Endometrial Cancer

Ashley Chan
March 14th 2025
Article

Palbociclib plus letrozole lengthened PFS vs placebo plus letrozole for patients with ER-positive advanced or recurrent endometrial cancer.

Oncology Nursing News

A Look Back at 2022 FDA Approvals in Oncology

Oncology Nursing News
January 2nd 2023
Podcast

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Simple line illustration of the female reproductive system with a tumor on the uterine lining, on a light blue background

Pembrolizumab Shows ORR, Tolerability in Previously Treated Gynecologic Cancer

Kristi Rosa
February 11th 2025
Article

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously treated CCGC.

light blue background with a white outline indicating a clipboard that says FDA

FDA Grants Breakthrough Status to Endometrial Cancer Assay

Kyle Doherty
February 9th 2025
Article

The FDA has granted breakthrough device designation to the ACR-368 OncoSignature assay for use in endometrial cancer.